CytomX Therapeutics, Inc.
Biotechnology · 200 employees
CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in
Funding history
- Series public offering — $244.0M — Mar 2026
- Funding Round — $30.0M — Aug 2023
- Funding Round — $70.0M — Jun 2015
Recent signals
- Mar 19, 2026: Raised $244.0M in Series public offering
- Mar 17, 2026: SEC 8-K (8.01): On March 17, 2026, CytomX Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Piper Sandler & Co., and Cantor Fitzgerald & Co., regarding the offering of 45,990,567 shares of the Company's common stock at an offering price of $5.30 per share. Additionally, the Company is offering pre-funded warrants for 1,179,245 shares of common stock at a price of $5.29999 per warrant. The Underwriting Agreement also grants the underwriters a 30-day option to purchase up to 7,075,471 additional shares at the public offering price, which indicates a strategic initiative to raise capital through the equity markets. This offering can potentially provide the necessary funds for the Company's operational and strategic objectives.
- Oct 20, 2025: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
- Mar 07, 2025: CytomX and Amgen End Partnership for T Cell Engager Development
- Jun 17, 2024: CytomX Therapeutics Appoints Chris Ogden as Chief Financial Officer
- Aug 17, 2023: Raised $30.0M
- Jul 17, 2023: CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
- Jun 25, 2015: Raised $70.0M
See plans & pricing → Track CytomX Therapeutics, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.